SecureTech Acquires 100% of AI UltraProd Group in Landmark Deal
Roseville, Minnesota, June 24, 2025 (GLOBE NEWSWIRE) -- SecureTech Innovations, Inc. (OTC: SCTH), a pioneering technology company advancing artificial intelligence, industrial 3D printing and manufacturing technologies, cybersecurity, and digital infrastructure solutions, is excited to announce its landmark acquisition of AI UltraProd Group (' AI UltraProd '). This strategic expansion strengthens SecureTech's ability to drive innovation, scale operations, and advance disruptive technologies that align with our 2025 Roadmap for Innovation and Growth, firmly positioning SecureTech for long-term success.
AI UltraProd Highlights:
FY2024 Revenue (audited): US$2.9 million
FY2025 Revenue (projected): US$10 million, with a substantial revenue surge anticipated in Q4 2025
Core Technology Advantage: Proprietary platform combining artificial intelligence with state-of-the-art industrial 3D printing technology and systems to deliver scalable, high-precision manufacturing solutions
Robust Intellectual Property Portfolio: 24 issued patents, one pending patent, and 20 additional patent applications underway, representing strong intellectual property protection and long-term technological innovation
Strategic Growth Outlook: SecureTech will aggressively expand and develop AI UltraProd for a potential spin-off onto the NASDAQ as an independent public company
Under the terms of the acquisition, SecureTech is committed to supporting AI UltraProd's growth trajectory over the next 24 to 36 months, backed by a planned investment of at least US$10 million through cash infusions and/or equity contributions. This funding will accelerate AI UltraProd's business expansion, scale operations, and refine its position as a key player in its industry. Further financial details, including two years of audited statements and combined pro forma financials, will be disclosed in a forthcoming SEC Form 8-K filing.
J. Scott Sitra, President and CEO of SecureTech, stated, 'The wait is over! SecureTech proudly announces that we have joined forces with powerhouse AI UltraProd to catapult us into a new era of innovation and industry dominance. AI UltraProd's cutting-edge fusion of AI and industrial 3D manufacturing is the perfect synergy with our relentless pursuit of technological excellence. As we integrate their expertise into our ecosystem, we're unlocking groundbreaking opportunities, pushing the boundaries of possibility, and creating long-term value for our shareholders like never before. The future is here, and SecureTech is leading the charge! None of this would be possible without the extraordinary dedication of our Roseville, Minnesota team and the visionary leadership of our Board of Directors', Sitra concluded.
Xing YunZhu, Director of AI UltraProd, commented, 'Partnering with SecureTech is a defining milestone in AI UltraProd's evolution. SecureTech's strategic investment and operational depth equip us to fast-track the deployment of our proprietary technologies, significantly scale production, and enhance our operational efficiency. Together, we're positioned to deliver high-performance, AI-powered manufacturing solutions to a broader range of industrial markets and customers—fueling the next phase of our growth.'
About AI UltraProd
AI UltraProd, Inc. specializes in revolutionizing industrial services and manufacturing by integrating breakthrough artificial intelligence with cutting-edge industrial 3D printing technology and machinery. This groundbreaking approach optimizes the entire process, from conceptual design to production to delivery management, dramatically reducing manufacturing times and costs while providing clients with a distinct competitive edge. AI UltraProd's growing intellectual property portfolio includes 24 issued patents, one pending patent, and 20 additional patents in development.
For more information, please visit www.aiultraprod.com.
About SecureTech Innovations
SecureTech Innovations, Inc. (OTC: SCTH) is a pioneering technology company advancing artificial intelligence, industrial 3D printing, cybersecurity, and digital infrastructures. Its portfolio includes AI UltraProd, a leader in AI-driven 3D industrial manufacturing; Piranha Blockchain, a developer of cutting-edge Web3 security, blockchain architecture, and digital asset reserves and security systems; and Top Kontrol, the only patented anti-theft and anti-carjacking system that can automatically stop a carjacking without requiring any driver action. SecureTech is committed to developing transformative solutions that address real-world challenges and problems.
For further information, visit our websites:
securetechinnovations.com | aiultraprod.com | piranhablockchain.com | topkontrol.com
This press release contains forward-looking statements that involve risks and uncertainties. Forward-looking statements refer to future events, expectations, plans, and prospects. SecureTech Innovations, Inc. (' SecureTech ') believes the expectations reflected in these forward-looking statements are reasonable as of the date they are made. However, actual results may differ materially from those expressed or implied by these forward-looking statements. SecureTech identifies forward-looking statements with words like 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately,' and similar expressions that convey uncertainty about future events or outcomes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market conditions and other circumstances. More detailed information about SecureTech and the risks that may affect these forward-looking statements can be found in SecureTech's filings with the Securities and Exchange Commission (' SEC '), including the risks contained in the section of our Annual Report filed on Form 10-K entitled 'Risk Factors.' These filings are available on the SEC's website at www.sec.gov.
Forward-looking statements in this press release speak only as of the date they are made. SecureTech has no obligation to update any forward-looking statements to reflect new events or circumstances after the date of this press release, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
28 minutes ago
- Globe and Mail
Migraine Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
DelveInsight's, 'Migraine Pipeline Insight 2025' report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Migraine pipeline landscape. It covers the Migraine pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Migraine Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Migraine Treatment Landscape. Click here to read more @ Migraine Pipeline Outlook Key Takeaways from the Migraine Pipeline Report On 17 August 2025, Teva Branded Pharmaceutical Products R&D LLC announced a study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study). On 15 August 2025, Pfizer conducted a study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks. Rimegepant is a tablet that dissolves when you put it on or under your tongue. On 15 August 2025, AbbVie announced a study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents. The study will include 2 cohorts of participants - PK Cohort and Main Study (non-PK cohort) DelveInsight's Migraine pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Migraine treatment. The leading Migraine Companies such as Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics and others. Promising Migraine Pipeline Therapies such as ALD403 (Eptinezumab), Ketorolac, Sumatriptan, divalproex sodium, Erenumab, GSK1838262, ALD403 and others. Stay informed about the cutting-edge advancements in Migraine Treatments. Download for updates and be a part of the revolution in Neurology care @ Migraine Clinical Trials Assessment Migraine Emerging Drugs Profile AXS-07: Axsome Therapeutics AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine. AXS-07 consists of MoSEIC (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan. AXS-07 is thought to act by inhibiting Calcitonin gene-related peptide (CGRP) release, reversing CGRP-mediated vasodilation, and inhibiting neuroinflammation, pain signal transmission, and central sensitization. Meloxicam is a new molecular entity for migraine enabled by MoSEIC™ technology, which results in rapid absorption of meloxicam while maintaining a long plasma half-life. AXS-07 is currently being developed for the acute treatment of migraine. The product is in the NDA submitted phase of development. STS-101: Satsuma Pharmaceuticals STS101 combines the Satsuma powder technology with an easy-to-use nasal delivery device to create a reliable and convenient DHE product potentially able to provide the unique clinical advantages of DHE while overcoming the shortcomings of existing DHE products. TS101 has a number of key advantages that we believe may provide significant benefits over other acute treatments for migraine and result in robust and consistent clinical performance. These advantages arise from our proprietary dry-powder formulation, which incorporates a mucoadhesive drug carrier and engineered drug particle technologies, and our proprietary nasal delivery device. STS101 is an investigational product that is currently being evaluated in Phase 3 clinical trials for the acute treatment of migraine and is not approved by the U.S. Food and Drug Administration. Zavegepant: Biohaven Pharmaceuticals Zavegepant (BHV-3500) is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist. The chemical properties of zavegepant make the product candidate potentially suitable for multiple routes of delivery, including nasal, subcutaneous, inhalation or oral is currently in Phase III stage of development for Migraine and is being developed by Biohaven Pharmaceuticals. TNX1900: Tonix Pharmaceuticals TNX-1900(Oxytocin), Tonix's proprietary potentiated intranasal oxytocin is in the pre-Investigational New Drug (IND) stage and is currently being studied as a candidate for prophylaxis of chronic migraine. Oxytocin is a naturally occurring human hormone that acts as a neurotransmitter in the brain. In clinical and preliminary research, it has been observed that increased oxytocin levels can relieve headaches. When oxytocin is delivered via the nasal route, it results in enhanced binding to receptors on neurons in the trigeminal system, inhibiting transmission of pain signals. Intranasal oxytocin has been well tolerated in several clinical trials in adults and children and has been shown to block calcitonin gene-related peptide (CGRP) release in animals, a pathway known to be critical to the pathogenesis of migraine attacks. TNX-1900 is believed to interrupt pain signals at the trigeminal ganglia by suppressing electrical impulses, a potentially different activity than drugs that just block CGRP. TNX-1900 is an investigational new drug and has not been approved for any indication. The Migraine pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Migraine with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Migraine Treatment. Migraine Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Migraine Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Migraine market. Get a detailed analysis of the latest innovations in the Migraine pipeline. Explore DelveInsight's expert-driven report today! @ Migraine Unmet Needs Migraine Companies Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics and others. Migraine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intra-articular Intraocular Intrathecal Intravenous Ophthalmic Oral Parenteral Subcutaneous Topical Transdermal Migraine Products have been categorized under various Molecule types such as Oligonucleotide Peptide Small molecule Discover the latest advancements in Migraine Treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Migraine Market Drivers and Barriers, and Future Perspectives Scope of the Migraine Pipeline Report Coverage- Global Migraine Companies- Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics and others. Migraine Pipeline Therapies- ALD403 (Eptinezumab), Ketorolac, Sumatriptan, divalproex sodium, Erenumab, GSK1838262, ALD403 and others. Migraine Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Migraine Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Migraine Pipeline on our website @ Migraine Emerging Drugs and Companies Table of Content Introduction Executive Summary Migraine: Overview Pipeline Therapeutics Therapeutic Assessment Migraine– DelveInsight's Analytical Perspective Late Stage Products (Pre-Registration) AXS-07: Axsome Therapeutics Drug profiles in the detailed report….. Last Stage Products (Phase III) STS-101: Satsuma Pharmaceuticals Drug profiles in the detailed report….. Mid Stage Products (Phase II) TNX1900: Tonix Pharmaceuticals Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company Name Drug profiles in the detailed report….. Inactive Products Migraine Key Companies Migraine Key Products Migraine - Unmet Needs Migraine - Market Drivers and Barriers Migraine - Future Perspectives and Conclusion Migraine Analyst Views Migraine Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
an hour ago
- Globe and Mail
Newegg Announces First Half 2025 Results
Newegg Commerce, Inc. (NASDAQ: NEGG) (the 'Company' or 'Newegg'), a leading global technology e-commerce retailer, today announced results for the six months ended June 30, 2025. 'Newegg experienced strong year-over-year growth in the first half of 2025, driven primarily by increased demand for GPUs and other core PC components, including the highly successful launch of the NVIDIA GeForce RTX 50 Series and AMD Radeon RX 9000 Series graphics cards, and AMD Ryzen 9000X3D Series CPUs,' said Newegg Chief Executive Officer Anthony Chow. 'These new product launches further boosted organic traffic and spurred robust cross-category purchasing, driving both topline growth and improved gross margins. We also benefited from pull-forward spending due to tariff uncertainty while simultaneously minimizing tariff impact on supply chain and customer experience through close collaboration with our key partners and suppliers. I am pleased with our results, and we will continue to be agile and opportunistic throughout the remainder of the year as we aim to deliver a superior experience for our loyal Newegg customers.' Newegg Interim Chief Financial Officer Christina Ching added, 'In the first half of 2025, Newegg demonstrated significant growth driven by robust sales of PC components, particularly boosted by positive momentum from the new GPU and CPU product launches. This strong consumer demand led to a 14% year-over-year increase in GMV and a 13% rise in net sales. Along with SG&A expense reductions following various strategic cost optimization measures throughout 2024 and 2025, our adjusted EBITDA improved substantially to $11.3 million for the six months ended June 30, 2025, up from a $7.3 million loss for the same period in 2024. We have also maintained focus on our cash balance and working capital. We also recently launched an 'at the market' (ATM) offering program, which we intend to use for general corporate purposes and working capital. As we move forward, our focus remains on maximizing market opportunities while navigating the ongoing tariff environment and other macroeconomic factors.' 2025 First Half Financial Highlights Net sales increased 12.6% to $695.7 million for the six months ended June 30, 2025, compared to $618.1 million for the six months ended June 30, 2024. GMV (defined below) increased 13.7% to $849.1 million for the six months ended June 30, 2025, compared to $746.7 million for the six months ended June 30, 2024. Gross profit increased 26.5% to $79.8 million for the six months ended June 30, 2025, compared to $63.1 million for the six months ended June 30, 2024. Net loss was $4.2 million for the six months ended June 30, 2025, compared to $25.0 million for the six months ended June 30, 2024. Adjusted EBITDA (defined below) was $11.3 million for the six months ended June 30, 2025, an increase of $18.6 million, compared to negative $7.3 million for the six months ended June 30, 2024. 2025 First Half Operational Metrics Average order value was $467 for the six months ended June 30, 2025, compared to $401 for same period in the prior year. Active customers, defined as unique customer IDs with at least one item purchased on Newegg platforms in the past six months, totaled approximately 1.13 million as of June 30, 2025, compared to 1.09 million for the same period in the prior year. Repeat purchase rate, which is the percentage of active customers who made at least two purchases on Newegg platforms during the past six months, was 25.2% as of June 30, 2025, compared to 23.0% for the same period in the prior year. Mr. Chow added, 'We are excited for several launches in the second half, including the expansion of our ABS line of PCs to high-performance workstations and tower servers, powered by industry-leading NVIDIA RTX PRO 6000 Blackwell graphic cards, helping businesses to explore and advance generative, agentic and physical AI. We will also be debuting our Gamer Community and Gamer Zone, which underscore our commitment to growing and supporting the gaming ecosystem, giving back to the very community that has fueled our success. We remain energized by our momentum, steadfast in optimizing our supply chain strategies to minimize any macroeconomic impacts, and confident in what lies ahead. ' About Newegg Newegg Commerce, Inc. (NASDAQ: NEGG), founded in 2001 and based in Diamond Bar, California, near Los Angeles, is a leading global online retailer for PC hardware, consumer electronics, gaming peripherals, home appliances, automotive and lifestyle technology. Newegg also serves businesses' e-commerce needs with marketing, supply chain, and technical solutions in a single platform. For more information, please visit Follow Newegg on X, TikTok, Instagram, Facebook, YouTube, Twitch, and Discord. Non-GAAP Financial Information This press release presents certain 'non-GAAP' financial measures. The components of these non-GAAP measures are computed by using amounts that are determined in accordance with accounting principles generally accepted in the United States of America ('GAAP'). A reconciliation of non-GAAP financial measures used in this press release to their nearest comparable GAAP financial measures is included in the schedules attached hereto. GMV The Company defines gross merchandise value, or GMV, as the total dollar value of products sold on its websites and third-party marketplace platforms, directly to customers and by its Marketplace sellers through Newegg Marketplace, net of returns, discounts, taxes, and cancellations. GMV also includes the services fees charged through its Newegg Partner Services in rendering services for its third-party logistics, shipped-by-Newegg, and media ad services, as well as the sales made by its Asia subsidiaries. Newegg believes that GMV helps it assess and analyze changes in revenues, and if reviewed in conjunction with net sales and other GAAP financial measures, can provide more information in evaluating its current performance and in assessing its future performance. Adjusted EBITDA Newegg calculates Adjusted EBITDA as net income/loss, excluding stock-based compensation expense, interest income, net, income tax (benefit) provision, depreciation and amortization expense, gain/loss from sales of fixed assets, gain/loss from sales of investment, and gain/loss from warrants liabilities. Newegg believes that exclusion of certain expenses in calculating Adjusted EBITDA facilitates operating performance comparisons on a period-to-period basis and excludes items that it does not consider to be indicative of its core operating performance. Accordingly, Newegg believes that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating its operating results in the same manner as its management and board of directors. Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of Newegg's results as reported under GAAP. Some of these limitations are: although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements; Adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs; Adjusted EBITDA does not consider the potentially dilutive impact of stock-based compensation; Adjusted EBITDA does not reflect tax payments that may represent a reduction in cash available to Newegg; and other companies, including companies in our industry, may calculate Adjusted EBITDA differently, which reduces its usefulness as a comparative measure. Because of these limitations, you should consider Adjusted EBITDA alongside other financial performance measures, including various cash flow metrics, operating profit and Newegg's other GAAP results. Cautionary Statement Concerning Forward-Looking Statements This news release includes 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements give our current expectations, opinions, beliefs or forecasts of future events and performance. A statement identified by the use of forward-looking words including 'will,' 'may,' 'expects,' 'projects,' 'plans,' 'believes,' 'should,' 'continue,' 'intend,' 'aim' and certain other statements about the future may be deemed forward-looking statements, including those regarding potential new product launches, the ability of new product launches to meet consumer needs, the Company's ability to navigate ongoing tariff uncertainty. Although Newegg believes that the expectations reflected in such forward-looking statements are reasonable at the time given, these statements involve risks and uncertainties that may cause actual future activities and results to be materially different from those suggested or described in this news release. These risks and uncertainties include changes in global economic and geopolitical conditions, fluctuations in customer demand and spending, inflation, interest rates and global supply chain constraints. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements in this press release are made as of the date hereof. The Company takes no obligation to update or correct its own forward-looking statements, except as required by law, or those prepared by third parties that are not paid for by the Company. The Company's SEC filings are available at June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 59,063 $ 96,255 Restricted cash 843 3,487 Accounts receivable, net 28,970 64,363 Inventories, net 152,859 98,537 Income taxes receivable 2,085 2,452 Prepaid expenses 11,440 14,222 Other current assets 4,559 4,329 Total current assets 259,819 283,645 Property and equipment, net 46,597 51,175 Noncurrent deferred tax assets 915 914 Right of use assets, net 54,474 60,636 Other noncurrent assets 10,932 10,951 Total assets $ 372,737 $ 407,321 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 118,031 $ 148,279 Accrued liabilities 37,192 48,629 Deferred revenue 23,619 26,988 Line of credit 15,775 7,069 Lease liabilities – current 12,815 12,608 Total current liabilities 207,432 243,573 Income taxes payable 1,795 1,871 Lease liabilities – noncurrent 46,864 53,318 Other liabilities 2,545 2,467 Total liabilities 258,636 301,229 Stockholders' Equity Common Stock, $0.43696 par value; unlimited shares authorized; 19,499 and 19,478 shares issued and outstanding as of June 30, 2025, and December 31, 2024, respectively 8,521 8,512 Additional paid-in capital 300,628 289,096 Notes receivable – related party (15,187 ) (15,189 ) Accumulated other comprehensive loss (1,653 ) (2,300 ) Accumulated deficit (178,208 ) (174,027 ) Total stockholders' equity 114,101 106,092 Total liabilities and stockholders' equity $ 372,737 $ 407,321 NEWEGG COMMERCE, INC. Consolidated Statements of Operations (In thousands) (Unaudited) Six Months Ended June 30, 2025 2024 Net sales $ 695,670 $ 618,119 Cost of sales 615,878 555,003 Gross profit 79,792 63,116 Selling, general, and administrative expenses 87,329 93,083 Loss from operations (7,537 ) (29,967 ) Interest income 1,058 1,544 Interest expense (466 ) (440 ) Other income, net 3,410 1,880 Gain from sales of investment - 1,619 Change in fair value of warrants liabilities (72 ) (64 ) Loss before provision for (benefit from) income taxes (3,607 ) (25,428 ) Provision for (benefit from) income taxes 574 (474 ) Net loss $ (4,181 ) $ (24,954 ) NEWEGG COMMERCE, INC. Consolidated Statements of Cash Flows (In thousands) (Unaudited) Six Months Ended June 30, 2025 2024 Cash flows from operating activities: Net loss $ (4,181 ) $ (24,954 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 4,425 5,739 Allowance for expected credit losses 20 1,193 Allowance for related party receivables 2 - Provision for obsolete and excess inventory 1,359 1,569 Stock-based compensation 11,630 15,022 Gain from sales of investment - (1,619 ) Change in fair value of warrant liabilities 72 65 Loss (gain) on disposal of property and equipment (643 ) 52 Unrealized gain on marketable securities - (10 ) Deferred income taxes - (169 ) Changes in operating assets and liabilities: Accounts receivable 35,377 42,426 Inventories (55,168 ) 2,223 Prepaid expenses 2,807 4,913 Other assets 6,533 8,959 Accounts payable (30,604 ) (95,388 ) Accrued liabilities and other liabilities (18,099 ) (15,036 ) Deferred revenue (3,482 ) (8,182 ) Net cash used in operating activities (49,952 ) (63,197 ) Cash flows from investing activities: Payments to acquire property and equipment (1,248 ) (1,212 ) Proceeds on disposal of property and equipment 2,723 15 Proceeds from sale of investment - 2,076 Net cash provided by investing activities 1,475 879 Cash flows from financing activities: Borrowings under line of credit 10,000 41,098 Repayments under line of credit (1,751 ) (27,474 ) Repayments of long-term debt - (132 ) Proceeds from exercise of stock options - 95 Payments for employee taxes related to stock compensation (89 ) (241 ) Payments for shares buyback - (3,503 ) Net cash provided by financing activities 8,160 9,843 Foreign currency effect on cash, cash equivalents and restricted cash 481 (886 ) Net decrease in cash, cash equivalents and restricted cash (39,836 ) (53,361 ) Cash, cash equivalents and restricted cash: Beginning of period 99,742 106,474 End of period $ 59,906 $ 53,113 Schedule 1 Reconciliation of Net Sales to GMV (In millions) (Unaudited) Six Months Ended June 30, 2025 2024 Net Sales $ 695.7 $ 618.1 Adjustments: GMV - Marketplace 173.0 153.0 Marketplace Commission (14.3 ) (12.7 ) Deferred Revenue (4.6 ) (5.8 ) Other (0.7 ) (5.9 ) GMV $ 849.1 $ 746.7 Schedule 2 Reconciliation of Net Loss to Adjusted EBITDA (In millions) (Unaudited) Six Months Ended June 30, 2025 2024 Net loss $ (4.2 ) $ (25.0 ) Adjustments: Stock-based compensation expenses 11.6 15.0 Interest income, net (0.6 ) (1.1 ) Income tax (benefit) provision 0.6 (0.4 ) Depreciation and amortization 4.4 5.7 Gain from sale of fixed assets (0.6 ) - Gain from sale of investment - (1.6 ) Loss from change in fair value of warrants liabilities 0.1 0.1 Adjusted EBITDA $ 11.3 $ (7.3 )
Globe and Mail
an hour ago
- Globe and Mail
Securities Fraud Investigation Into Coty Inc. (COTY) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announces an investigation of Coty Inc. ('Coty' or the 'Company') (NYSE: COTY) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON COTY INC. (COTY), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On August 20, 2025, Coty released its fourth quarter fiscal 2025 financial results and revealed that the Company's results were negatively impacted by, among other things, 'retailer destocking.' The Company further disclosed that it was 'continuing to clean the baseline, including assuring that retailer inventories are rightsized relative to current demand trends to drive alignment between sell-in and sell-out.' On this news, Coty's stock price fell $1.05, or 21.6%, to close at $3.81 per share on August 21, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Coty securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 Call us at: 310-914-5007 Email us at: info@ Visit our website at: Follow us for updates on Twitter at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
